Drug intelligence / Profile preview

BPP-2001

Development stage: Preclinical
Lead developer: Beta Pharma
Modality: Peptides
Administration: Subcutaneous

Overview

BPP-2001 is an investigational peptide-based therapeutic being developed by Beta Pharma for weight management and the treatment of obesity. It functions as an agonist of the glucagon-like peptide (GLP) receptor, a validated biological pathway for regulating appetite, enhancing satiety, and improving metabolic health. BPP-2001 is part of Beta Pharma's metabolic disease pipeline, which focuses on leveraging GLP-related mechanisms to address the growing global prevalence of overweight and obesity conditions.

Targets

GLP1R (GLP-1R)

Beyond the preview

Go deeper on BPP-2001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BPP-2001.

Explore the full profile